Diabetes drug metformin recall expands over cancer risk

The US Food and Drug Administration has published a voluntary recall announced by Nostrum Laboratories on Monday. The notice expands the number of Metformin HCl Extended-Release Tablets recalled over potentially high levels of a probable human carcinogen called N-Nitrosodimethylamine, more commonly referred to as ‘NDMA.’ We saw multiple metformin recalls throughout 2020, all of them over potentially high NDMA levels, …